September 27, 2019 – Marlborough, Mass., and Paramus, N.J. , – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced the initiation of the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for SEP-363856, a novel agent for the treatment of adults and adolescents with schizophrenia. The global, multicenter program includes four studies that are designed to evaluate the safety, efficacy and tolerability of SEP-363856. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for SEP-363856 in May 2019.
